|Articles|January 18, 2022
Support for Title 21 CFR Part 11 and Annex 11 Compliance
Author(s)Agilent
This paper describes the requirements for electronic records and electronic signatures for regulated pharmaceutical organizations.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
5